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  VWF exposure following plaque rupture tethers platelets to support adhesion, 
activation and aggregation 
  MMP-13 is also associated with and released upon plaque rupture  
  Unlike ADAMTS-13, MMP-13 is able to cleave VWF under static conditions  
  MMP-13-cleaved VWF binds more strongly to platelets forming denser thrombi 





BACKGROUND: Atherosclerotic plaque rupture and subsequent thrombosis underpin 
thrombotic syndromes.  Under inflammatory conditions in the unstable plaque, 
perturbed endothelial cells secrete von Willebrand Factor (VWF) which, via its 
interaction with GpIbα, enables platelet rolling across and adherence to the damaged 
endothelium. Following plaque rupture, VWF and platelets are exposed to subendothelial 
collagen which supports stable platelet adhesion, activation and aggregation. Plaque-
derived matrix metalloproteinase (MMP)-13 is also released into the surrounding lumen 
where it may interact with VWF, collagen and platelets.  OBJECTIVES: We sought to 
discover whether MMP-13 can cleave VWF and whether this might regulate its 
interaction with both collagen and platelets. METHODS: We have used platelet adhesion 
assays and whole blood flow experiments assess the effects of VWF cleavage by MMP-13 
on platelet adhesion and thrombus formation.  RESULTS: Unlike the shear-dependent 
cleavage of VWF by ADAMTS13, MMP-13 is able to cleave VWF under static conditions. 
Following cleavage by MMP-13, immobilised VWF cannot bind to collagen but interacts 
more strongly with platelets, supporting slower platelet rolling in whole blood under 
shear. Compared with intact VWF, the interaction of cleaved VWF with platelets results 
in greater GpIbα up-regulation and P-selectin expression, and the thrombi formed on 
cleaved VWF–collagen co-coatings are larger and more contractile than platelet 
aggregates on intact VWF-collagen co-coatings or on collagen alone. CONCLUSIONS: 
Our data suggest a VWF-mediated role for MMP-13 in the recruitment of platelets to the 
site of vascular injury and may provide new insights into the association of MMP-13 in 




Von Willebrand Factor (VWF) is a large multimeric adhesive glycoprotein selectively 
produced in megakaryocytes (MKs) and endothelial cells (ECs)[1]. Patients with von 
Willebrand disease lack functional VWF protein and exhibit a moderate to severe 
haemorrhagic phenotype[2]. Mature multimers of VWF are released into the blood from 
storage in Weibel-Palade bodies in ECs and from α-granules in activated platelets. The VWF 
protein has a multi-domain structure comprising D1-D2-D’-D3-A1-A2-A3-D4-C1-C2-C3-C4-
C5-C6-CK[3]. Under static conditions, secreted VWF adopts a globular conformation, but 
under shear, unfolds to expose platelet and collagen binding sites[4]: The A1 domain is no 
longer protected by the D3 domain and can bind to GpIbα on the platelet surface, while both 
the A1 and A3 domains are able to bind to fibrillar collagens[5]. VWF itself multimerizes to 
form highly thrombogenic ultra-large multimers (UL-VWF) which are in part regulated by 
ADAMTS (a disintegrin and metalloprotease with thrombospondin motif)-13 which binds to 
and under shear cleaves VWF at the A2 domain generating smaller, less reactive VWF 
aggregates.  
MMPs are proteolytic enzymes which mediate the degradation of many extracellular matrix 
and cell surface proteins, and are secreted as pro–enzymes which are activated following 
cleavage of the pro–peptide domain. Under inflammatory conditions such as those in the 
vulnerable plaque, increased MMP-13 expression and release following plaque rupture[6-8] 
brings the MMP into contact with plasma proteins, blood cells and platelets. MMP-13 is 
implicated in the early pathology of stroke progression, with plasma MMP-13 levels reaching 
in excess of 10 ng/ml (200 nM) in the blood of stroke patients[9, 10].  A high plasma level of 
VWF is known to be associated with the development of cardiovascul r disease and, may 
predict stroke[11], while low levels of ADAMTS13 are associated with an increased risk of 
thrombosis and ischaemic stroke[12]. MMP levels have also been shown to be 8-fold greater 
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in atheromatous plaques than in normal vessels[13]. Given that collagen and VWF are known 
to act synergistically in supporting platelet adhesion at the site of injury[14], it is not 
unreasonable to hypothesise that cleavage of VWF by MMP-13 may serve to reduce the degree 
of platelet activation and adhesion in thrombus formation. In this study, we aimed to determine 
the effects of MMP-13-mediated degradation of VWF on platelet adhesion under both static 
and flow conditions. In contrast to the hypothesis above, we show here that while MMP-13-




MATERIALS & METHODS 
MMP-13 expression, purification and activation 
ProMMP-13 was expressed, purified, activated and dialysed as previously described[15-17]. 
ProMMP-13 was activated using 1 mM (final concentration) 4-Aminophenylmercuric acetate 
for 1 h at 37 °C prior to dialysis for 4 h at 4 °C. The structurally homologous but catalytically 
inactive MMP-13(E204A) was a kind gift from Dr R. Visse (Kennedy Institute of 
Rheumatology Division, Imperial College London, London, UK)[15, 16].  The (Cat)alytic 
domain of MMP-13 (249-451) was expressed and purified from NSO mouse myeloma cells 
as previously described[18]. MMP-13 GST-Hemopexin (Hpx) domain was expressed in E. coli 
using the pGEX-2T expression vector, the forward primer 
TCCGCGTGGATCCCTCTATGGTCCAGGAGATGAA and the reverse primer GCAA-
ATTCCATTTTGTGGTGTTGAAGAATTCAT, which contain BamHI and EcoRI restriction 
sites respectively, as previously described[19]. 
 
Cleavage of VWF by MMP-13 
Purified human VWF (ab88533; abcam, Cambridge, UK) at 0.2 mg/ml (final concentration in 
Tris pH 7.4) was incubated with MMP-13 or ADAMTS13 (6156-AD-020; R&D Systems, 
Abingdon, Oxford, UK) at 1.5 µM final enzyme concentration for 2 h at 37 °C. MMP-13 alone 
was also incubated with Tris buffer at 37 °C alongside the cleavage experiments in order to 
generate autolysed (AL)MMP-13 for use as a negative control. Reducing sample buffer was 
then added to the mixture prior to electrophoresis and Western blotting. Following incubation 
with MMP-13, cleaved VWF was transferred onto PVDF membrane which was then stained 
with 0.1 % Coomassie R250, 40 % MeOH, 1 % HAc to allow the visualisation of protein bands 
and dried. The MMP-13 cleavage sites on VWF were identified by Edman degradation using 
an ABI Procise 494HT Protein Sequencer©. 
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Electrophoresis and Western blotting 
Protein samples in reducing sample buffer were boiled for 5 min and applied to 4-12 % 
NuPage® Gels and separated by electrophoresis using the Xcell SureLock™ system 
(Invitrogen) under reducing conditions.  Proteins were then ra sferred on to nitrocellulose 
membrane (Millipore, Bedford, UK) at 80 V for 1 h using a Hoefer semi-dry blotting system 
(Holliston, MA, USA).  Following transfer, the membrane was blocked (5 % BSA, 0.1 % 
Tween 20 in TBS) for 1 h. Rabbit anti-VWF (ab9378; abcam, Cambridge, UK) was incubated 
with the membrane overnight at 4 °C at a dilution of 1:1000.  Following washes with TBST, 
the membrane was incubated with HRP conjugated goat anti-rabbit at 1:10000 dilution (P0448; 
Dako, Stockport, UK) for 1 h at 24 °C.  The membrane was developed using a 
chemiluminescent substrate (RPN2209; GE Healthcare, Amersham, Bucks, UK).  
 
Collagen Toolkit Peptide design and synthesis– Collagen Toolkit II and III peptides were 
generated using a CEM Liberty microwave-assisted solid-phase peptide synthesizer and N-(9-
fluorenyl)methoxycarbonyl (Fmoc) chemistry as previously described[19, 20].  All peptides 
were verified using MALDI-TOF mass spectrometry. Their triple-helical conformation, 
verified by polarimetry is maintained by the flanking sequences, GPC(GPP)5- and -(GPP)5-
GPC-amide, at their N- and C-terminus respectively.  For simplicity, peptides are referred to 
by their specific guest sequence.  A negative control peptide, (GPC-(GPP)10-GPC-amide) is 
referred to as GPP10.   
 
Solid phase binding assays 
Collagen Toolkit assays- HB 96-well plates (Nunc, Langenselbold, Germany) were coated 
with either collagen Toolkit peptides or fibrillar or monomeric collagen at a saturating 
concentration (10 µg/ml in 0.01 M acetic acid). All incubations were performed at 24 °C for 1 
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h unless otherwise stated in the presence of 2 mM Mg2+.  The wells were washed three times 
with adhesion buffer (1 mg/ml BSA in Tris-Buffered Saline (TBS) containing 0.1 % (v/v) 
Tween-20) between each incubation step.  Wells were blocked with 50 mg/ml BSA in TBS 
prior to the addition of VWF at a concentration of 5 µg/ml in adhesion buffer.  Where indicated, 
intact VWF was pre-incubated with 83 nM MMP-13(E204A) for 1 h prior to adhesion assays.   
Rabbit anti-VWF raised against the whole molecule (abcam, Cambridge, UK), and goat anti-
rabbit HRP (Dako, Ely, UK) were added at a dilution of 1:2000 in adhesion buffer prior to the 
addition of TMB substrate system (T0440; Sigma) and the plat s read at 450 nm.   
Antibody affinity assay- HB 96-well plates were coated with intact or cleaved VWF (5 µg/ml 
in TBS for 1 h at 24 °C.  All further incubations were performed at room temperature for 1 h 
unless otherwise stated.  The wells were washed three times with adhesion buffer between each 
incubation step.  The wells were then blocked with 50 mg/ml BSA in TBS prior to antibody 
addition and detection as described for collagen Toolkit assays.  
VWF recognition of MMP-13- HB 96-well plates were coated with 83 nM proMMP-13 in 
TBS for 1 h at 24 °C.  All further incubations were performed as previously described for 
collagen Toolkit assays.  
 
Washed platelet preparation and platelet adhesion xCELLigence assays 
Platelets were purified and adhesion assays conducted as previously described[21, 22].  Fibrous 
collagen type I was a gift from Ethicon Corp, Somerville, NJ, USA. Ninety-six-well 
xCELLigence E-plates (ACEA Biosciences, San Diego, CA, USA) were coated with type I 
collagen or intact or cleaved VWF (10 µg/ml) in Phosphate-Buffered Saline (PBS) for 1 h at 
24 °C. Wells were also coated with autolysed MMP (800 nM) as a negative control. The wells 
were then blocked with 2 mg/ml BSA in TBS and 50 µl calcium-free Tyrodes (CFT) buffer 
added as a baseline. Fifty microlitre aliquots of 2x108 platelets/ ml in CFT were pre-incubated 
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for 1 h with the αIIbβ3 inhibitor 1-10 µM GR144053 (4-[4-[4-(aminoiminomethyl]-1-
piperazinyl]-1-piperidineacetic acid hydrochloride trihydrate; Calbiochem, Nottingham, UK) 
or 10-50 µg/ml of the GpIbα inhibitor Myr-Ser-Ile-Arg-Tyr-Ser-Gly-His-Ser(PO3H2)-Leu 
(ab143739; abcam, Cambridge, UK) where indicated. xCELLigence xp riments were allowed 
to proceed for 1 h at 37 °C and platelet binding measured as Cell Index. 
 
Whole blood perfusion experiments 
Blood from healthy medication-free volunteers was colle ted into 40 μM PPACK and 
supplemented hourly with 10 µM PPACK. Blood was incubated with 1 μM 
3,3′dihexyloxacarbocyanine iodide (DiOC6) for 15 min before use. Blood was pre-incubated 
with 10 µM GR144053 or 50 µg/ml Myr-Ser-Ile-Arg-Tyr-Ser-Gly-His-Ser(PO3H2)-Leu for 1 
h where indicated. Blood was perfused over 10 µg/ml VWF and/or type I fibrous collagen-
coated slide as previously described[21, 23].  Where indicated, slides were coated with 
(AL)MMP-13 alone as a (negative) control. Thrombi were measured using an UplanFLN 40× 
NA1.30 oil immersion objective and a field size of 360 μm × 360 μm on an Olympus FV300 
confocal microscope.  
Blood was perfused at a shear rate of 1000 s−1 for 5 min with images being acquired every 5 s 
at the plane of the thrombogenic surface. Images were export d to ImageJ1.35 (National 
Institutes of Health) for analysis. Thresholding the coverslip plane optimized contrast; a 
manipulation which when applied to all images allowed measurements of particle size and 
count. Thrombus area covering the coverslip plane yielded the primary measurement of surface 
coverage (SC). Z-stacks (sequential vertical images of a given field; ΔZ = 0.69 μm, and 
encompassing the entire thrombus height) were used to calculate thrombus volume as the sum 
of the detected surface areas of all images of the Z-stack, multiplied by ΔZ. This value is 
divided by the field area (giving units of μm3/μm2) providing a free-standing measure of 
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thrombus formation, and although a volume measurement has he units of microns is referred 
to as mean thrombus height. A separate measure of the absolute height of the thrombus, ZV50, 
was calculated as the Z-height at which thrombus volume was half-maximal. Platelet rolling 
measurements were taken as previously described using the SC calculated for each image 
during the timecourse, subtracted from a duplicated single frame offset image to yield the 
change in surface distribution with time (dSD/dT) as previously described[24]. dSD/dT 
expressed relative to SC of the corresponding, unprocessed frame produces dSD/dT/SC; a 
measurement of the rate of change of platelet capture ranging from a numerical values of 1 for 
100 % rolling and 0 for static, adherent platelets. 
 
Immunofluorescence  
All samples were imaged using an Olympus UplanFLN 40× NA1.30 oil immersion objective 
and a field size of 360 μm × 360 μm. 
VWF adhesion to collagen fibres- Glass slides were coated with 100 µg/ml type I collagen for 
1 h at 24 °C. Slides were then washed with PBS and overlaid with 5 µg/ml intact or cleaved 
VWF for 1 h at 24 °C. After washing, bound VWF was detected using rabbit anti-VWF (1:2000 
dilution; abcam, Cambridge, UK) overnight at 4 °C and FITC-conjugated anti-rabbit (Sigma, 
UK) for 1 h at 24 °C. 
GpIbα and P-selectin immunofluorescence- Following whole blood perfusion experiments, 
adherent platelets were fixed with 10 % neutral buffered formalin for 30 min. The slides were 
blocked with 1 % BSA for 1 h prior to the addition of 1:1000 dilution anti-human GpIbα 
(AF4067; R&D Systems, Abingdon, Oxford, UK) or anti-P-selectin (ab6632; abcam, 
Cambridge, UK) overnight at 4 °C. Slides were washed and anti-sheep-FITC (F5137; Sigma, 
UK) or anti-mouse Alexa-647 (115-606-008; Jackson ImmunoResearch, Ely, UK) conjugated 
secondary antibodies added for 1 h at 24 °C prior to washing. Images were then exported to 
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ImageJ1.35 for analysis. Overall fluorescence was measured as Mean Gray area. Images were 
subjected to thresholding in order to obtain fluorescent surface area.  




Incubation with MMP-13 but not ADAMTS13 resulted in the cleavage of VWF under static 
conditions (Figure 1A). After incubation for 2 h at 37 °C, ADAMTS13 remained intact whereas 
MMP-13 had completely autolysed. ProMMP-13 exhibited some proteolytic activity against 
VWF (due to a degree of autolysis into active MMP), though as expected cleavage was less 
aggressive than that observed for the active form of the enzyme. MMP-13 was also able to 
cleave VWF incubated in human plasma and so is active in vitro (as seen by an increased 
number of degradation products in Supplemental Figure 1B). Sequence analysis of the main 
degradation products (bands designated 1, 2 and 3 in Figure 1A) revealed cleavage sites of 
PGG~LVV, EDI~SEP and EQC~LVP; the first two of which are located in close together just 
before the A1 domain at residues 1243 and 1262 respectively. The third is located in the C8-4 
region of the D domain cluster (Figure 1B). Low molecular weight bands (5-10 kDa) of fully 
the unstable autolysed (AL)MMP-13 but not the more stable ADAMTS13 are also visible 
following incubation. Solid phase binding assays to collagen and Toolkit peptides revealed that 
as expected, intact VWF was able to bind to collagens I, II and III and its target Toolkit peptides 
II -22 and III-23[25], however cleavage of VWF by MMP-13 completely abolished adhesion to 
both Toolkit peptides and greatly reduced adhesion to all collagen types tested (Figure 2A). 
Fluorescence microscopy of VWF bound to collagen I fibres corroborated these results, with 
the binding of MMP-13-cleaved VWF greatly reduced over that of its intact counterpart (Figure 
2B). Although cleaved VWF contains some (AL)MMP-13, this form of the enzyme is unable 
to unwind and therefore to cleave the collagen substrate.  In addition, although VWF does 
adhere to MMP-13 (and to a lesser extent its composite domains) s seen in Supplemental 
Figure 1A, this interaction does not impede the binding of VWF to its target Toolkit peptides 
(Supplemental Figure 1B). Antibody affinity assays revealed no difference in detection 
between intact and MMP-cleaved VWF (Figure 2C). 
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Washed platelet adhesion to cleaved VWF was significantly higher than that observed for intact 
VWF or autolysed MMP-13 alone, which supported only low levels of binding (Figure 3A; p 
˂ 0.01 One-way ANOVA with post-hoc Tukey HSD test). Whole blood platelet rolling on 
cleaved VWF was also significantly slower than on intact VWF (Figure 3B) although 
interestingly, platelet thrombus surface coverage, height and ZV50 were not differentially 
affected (Figure 3C i-iii). In separate stand-alone experiments, washed platelet adhesion, 
rolling and thrombus deposition on intact VWF compared with in act VWF co-coated with 
autolysed (AL)MMP-13 were not significantly different (Supplemental Figure 2A, B and Ci-
iii respectively). Blockade of platelet receptors αIIbβ3 and GpIbα with 10 µM GR144053 and 
50 µg/ml Myr-Ser-Ile-Arg-Tyr-Ser-Gly-His-Ser(PO3H2)-Leu (myr-SIRYSGHS(P)L) 
respectively significantly reduced platelet adhesion to cleaved VWF (Figure 4A) with both 
inhibitors combined exerting maximal effect, returning adhesion to the intact VWF baseline (p 
< 0.01; One-way ANOVA with post-hoc Tukey HSD test). In platelet rolling experiments, pre-
incubation of whole blood with 50 µM (myr-SIRYSGHS(P)L) caused a reversion to the intact 
VWF phenotype (Figure 4B), indicating that the increase in adhesion and slower rolling rates 
are due primarily to a stronger/longer GpIbα:platelet attachment. Platelet surface coverage, 
thrombus height, and ZV50 were not significantly altered betwe n parallel assays on intact and 
cleaved VWF. 
Immunofluorescence experiments post-blood flow revealed that both platelet GpIbα and P-
selectin expression were significantly increased (Figure 5A) on platelets adherent on cleaved 
vs. intact VWF (each p < 0.05, two-tailed paired t-Test; Figure 5Bi and ii). Both GpIbα and P-
selectin were up-regulated approximately two-fold in response to adhesion to cleaved VWF 
(Figure 5Biii). As expected, the GpIbα fluorescent surface area on cleaved and intact VWF 
were very similar (Figure 5Ci), indicating the same number of adherent platelets expressing 
the receptor, albeit by differing amounts (and thus fluorescence intensity) between conditions 
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(Figure 5Bi). A significant increase (p = 0.02) in fluorescent surface area corresponding to an 
increase in the number of platelets expressing P-selectin was observed, however (Figure 5Cii), 
indicating a greater degree of platelet activation and reinforcing our solid-phase binding assay 
observations. 
Co-coating collagen I fibres with intact and cleaved VWF prior to whole blood flow resulted 
in a slight but significant increase in surface coverage elative to collagen I alone (intact VWF, 
p = 0.0083 and cleaved VWF, p = 0.0143; Figure 6Ai). No significant change was observed in 
mean thrombus height or ZV50 (Figure 6Ai and ii). Thrombus morphologies, however, differed 
considerably between collagen co-coated with intact and cleaved VWF (Figure 6Bi). Image 
analysis revealed that co-coating VWF with collagen produced thrombi with significantly 
larger particle size (Figure 6Bii) and correspondingly lower particle count than with collagen 
alone (Figure 6Biii), but co-coating with cleaved VWF led to a further increase in particle size, 
significantly greater than collagen I, both alone and co-coated with intact VWF (Figure 6Bii 
and iii). In essence, thrombi formed on co-coated cleaved VWF were less fragmented, and 
although covering the same surface area as those on co-coated intact VWF, formed larger, more 
contiguous, denser thrombi. We theorised that such apparently tighter aggregates might occur 
due to greater platelet contraction within the thrombi. When the final binary image, obtained 
at t = 300 s, was subtracted from that at t = 250 s, an outline corr sponding to the degree of 
contraction of thrombi was clearly visible (Figure 7). This effect was most marked for co-
coatings of collagen I with cleaved VWF, then with intact VWF, which in turn was greater than 
collagen I alone, indicating that the highest degree of retraction occurred with exposure to 
cleaved VWF.   
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DISCUSSION 
Platelets adhere to sites of vascular injury to halt bleeding. Membrane receptors that promote 
adhesion are essential for platelet tethering and arrest on the exposed endothelial surface. The 
initial rolling of platelets on VWF under shear is mediated largely by its interactions with the 
glycoprotein-Ibα (GPIbα) subunit of the platelet GPIb-IX-V complex and subsequently with 
the integrin αIIbβ3. αIIbβ3, the primary platelet fibrinogen receptor, can also bind the VWF 
C4-8 module[26], while glycoprotein GpIbα binds to the A1 domain of VWF, both attached to 
platelets and immobilised on collagen exposed in the vessel wall[27].  
MMP-13 is a collagenolytic protease whose presence and activity is up-regulated in unstable 
atherosclerotic lesions which has  predominant role in mediating plaque rupture[6]. Most 
MMPs, however, have many substrates and here we show that MMP-13 can also cleave VWF 
under static conditions. This ability sets it apart from ADAMTS13, a circulating 
metalloproteinase which cleaves highly thrombotic ultra la ge VWF multimers into smaller 
fragments but only when the A2 domain of VWF is accessible under shear conditions[28]. 
ADAMTS13 cleavage of unfolded VWF safeguards against the accumulation of ultra large 
VWF multimers and the subsequent formation of platelet aggregates that may occlude 
arterioles and capillaries[29]. Here we show that MMP-13 cleaves VWF at three main sites, 
two just prior to the A1 domain, and the third in the C8-4 domain. Under inflammatory 
conditions and following plaque rupture, this multi-site cleavage of VWF is likely to result in 
the presence of VWF in various stages of proteolysis and h s istinct consequences for collagen 
and platelet binding. The ability of such cleaved VWF to bind to collagen and to Toolkit 
peptides was virtually abolished, while its platelet binding capacity increased. VWF binds to 
collagen primarily through its A3 domain, although in its absence, the A1 domain can substitute 
for A3 under flow conditions[30]. Proteolytic degradation of VWF has previously been shown 
to impair its binding to microtiter plates coated with human collagen[31], and VWF multimer 
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defects, depending upon the degree of structural abnormality, often result in low collagen 
binding [32]. It would therefore appear that cleavage of VWF, for example by MMP-13, can 
result in altered protein organisation which masks the collagen binding motifs in the A1 and 
A3 domains. 
In contrast, MMP-13-cleaved VWF was able to support a much higher degree of platelet 
adhesion under static conditions than intact VWF. Cleaved VWF also supported slower platelet 
rolling than intact VWF, indicating that cleaved VWF adopts a conformation that supports a 
longer or stronger interaction with platelets. The A1 domain of VWF forms an autoinhibitory 
module that masks the A1 domain[33]. Cleavage of VWF just prior to the A1 domain may 
release it from protection by the D3 domain and/or destabilise the N-terminus of the A1 domain 
to expose the GPIbα binding site[34]. In addition, the sequence length of the N-terminal 
flanking region preceding the A1 domain has been shown to affect the ability of the A1 domain 
to interact with platelet GpIbα[35]. Cleavage of VWF by MMP-13 in this region could 
therefore be expected to modulate this interaction.  Interes ingly, limited proteolysis of VWF 
by trypsin also yields a conformational change in VWF that promotes ristocetin-induced GpIbα 
binding, which may occur via a similar mechanism[36]. The actions of VWF are mediated via 
two main platelet receptors, GpIbα (as part of the GPIb-V-IX complex) and αIIbβ3; with the 
former mediating platelet adhesion and the latter orchestrating the resulting platelet 
aggregation. Upon interaction with VWF, GpIb-V-IX initiates transmembrane signalling 
events which result in αIIbβ3 activation and platelet aggregation[27]. Platelets adherent to 
coated ‘solid phase’ VWF express a concentration-dependent increase in GpIbα expression, 
but not αIIbβ3[37]. Here we show that cleavage of VWF augments this effect, increasing GpIbα 
expression levels on adherent platelets over those ob rved with intact VWF. Tethering of 
platelets under high shear almost exclusively via GpIbα makes this receptor pivotal to 
haemostasis[27]. The slower rate of whole blood platelet rolling on cleaved VWF was nullified 
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following GpIbα inhibition, and, after rolling experiments, platelets adherent to cleaved VWF 
displayed correspondingly (2-fold) higher levels of b th GpIbα and P-selectin expression, 
suggesting a greater degree of GpIbα-mediated platelet activation. These observations were 
supported by our solid phase binding assays in which antagonists of both GpIbα and αIIbβ3 
reduced washed platelet binding to intact VWF levels. 
Although platelets roll on immobilised VWF, they require lgands in exposed connective tissue 
for firm adhesion and aggregation. VWF presented on the vessel wall is usually co-localised 
with newly exposed collagen[38]. Although all of the platelets within a thrombus are likely to 
interact with VWF, only those closely packed in the centre ormally become pro-coagulant 
and P-selectin positive[39].  Collagen and VWF are known to ac  synergistically in supporting 
platelet adhesion at the site of injury[14]. Although MMP-13-cleavage of VWF abolishes its 
ability to bind to fibrillar collagen, cleaved VWF is still able to adhere to platelet GpIbα and 
αIIbβ3 and would co-localise with the exposed collagen. VWF also interacts wi h laminin, 
fibronectin, thrombospondin, and vitronectin within the ECM to maintain a substrate platform 
during thrombus formation. The question was therefore whether slowing of platelet rolling and 
a greater degree of platelet activation in the presence of l aved VWF is sufficient to result in 
greater/firmer platelet adhesion and the formation of larger thrombi. Co-coating intact and 
cleaved VWF with fibrillar collagen I resulted in a small but significant increase in thrombus 
surface area, however the most striking observation was the change in thrombus morphology 
between conditions. Platelet aggregates formed on cleaved co-coated VWF were significantly 
larger than those on co-coated intact VWF and collagen alone, with far fewer separate platelets 
or smaller outlying thrombi. These larger, more-amalgamated thrombi translated into an overall 
increased mean particle size and correspondingly lower particle count.  GpIb-V-IX and αIIbβ3 
are known to have large role in platelet mechanobiology; the adhesion of VWF to GpIbα can 
trigger mechanotransduction and platelet activation by enhancing the drag force applied on the 
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cell-surface receptor[40] and both receptors work together to mediate platelet shape change 
and contraction during activation and aggregation[41]. We hypothesised that these more dense 
thrombi, likely to contain a larger proportion of active plate ets, may result in a greater degree 
of clot contraction in the latter stages of thrombus formation. Image subtraction of end-stage 
thrombi from those obtained 50 s earlier confirmed that te platelet aggregates on cleaved co-
coated VWF contracted more than those on intact co-coated VWF or collagen I alone. Platelet-
driven clot contraction is crucial for haemostasis, wound healing and the restoration of blood 
flow past otherwise obstructive thrombi[42]. Contraction, however, can also confer a resistance 
to clot lysis therapies[43].  Atherosclerotic plaque rupture, thrombosis and its associated 
pathologies including stroke, reperfusion injury and haemorrhagic transformation are 
associated with an upregulation of MMP activity, with MMP-9 and -13 implicated in the early 
pathology of stroke progression[9, 10, 44]. Here we demonstrate that the cleavage of VWF by 
MMP-13 perturbs two distinct processes integral to the process of thrombus formation; on the 
one hand inhibiting VWF adhesion to collagen, but increasing platelet activation in thrombi 
formed in flowing whole blood.  It may be that in this way MMP-13 plays its role in the 
pathology of ischaemic stroke; mediating the formation of highly contractile thrombi which 
may be more resistant to lysis therapies and which are also more prone to detachment from the 
collagen-rich vessel wall.  MMP-13 would appear therefore to modulate the architecture of 
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 FIGURE LEGENDS 
 
Figure 1.  Cleavage of VWF by MMP-13.  (A) SDS-PAGE of cleaved VWF samples. MMP-
13 but not ADAMTS13 at a concentration of 1.5 µM was able to cleave purified human VWF 
(0.2 mg/ml) after 2 h at 37 °C. Degradation products were analysed by (i) 12 % reducing SDS-
PAGE and (ii) overnight separation of high molecular weight multimers on 15 % acrylamide 
gels at 4 °C. (B) Schematic representation of MMP-13 cleavage sites on VWF. Sequence 
analysis of MMP-13 cleavage sites revealed two N-terminal to the A1 domain and one within 
the C8-4 domain. The ADAMTS13 cleavage site within the A2 domain is also marked for 
reference.  
 
Figure 2.  Antibody recognition of VWF and adhesion of VWF to collagen and collagen 
Toolkit peptides. (A) Plates were coated with 10 µg/ml Toolkit II peptides, fibrillar type I 
collagen and the negative binding peptide GPP10. Intact VWF (black bars) and cleaved VWF 
(grey bars) at a concentration of 5 µg/ml were allowed to adhere to the peptides for 1 h at room 
temperature. Data represent mean A450 ± S.E. of three experiments. (B) Intact and cleaved 
VWF were allowed to adhere to fibrillar collagen type I coated glass slides for 1 h at room 
temperature and detected using an anti-VWF primary and FITC-linked secondary antibody. 
Images are representative of three replicate experiments. 
 
Figure 3.  Platelet adhesion, rolling and thrombus formation on intact and cleaved VWF.  
(A) Binding of washed platelets to intact and cleaved VWF in xCELLigence solid phase 
binding assays. Collagen type I, autolysed MMP-13 and BSA were used as control substrates. 
** p < .001; (one-way ANOVA and post-hoc Tukey HSD test). Data represent mean S. E. of 
twelve separate donors. (B) Whole blood platelet rolling at a shear rate of 1000s-1 on intact 
(black circles) and cleaved (open circles) VWF. ds/ddt is used a  a measurement of platelet 
motility with a measurement of 1 and 0 indicating fully rolling and fully adherent platelets 
respectively. Data represent mean ± S.E. of thirteen separat  donors. 95% confidence intervals 
are also shown for the best fit lines, calculated by Linear Regression (Prism 6).  (C) Deposition 
of platelets on MMP-13 VWF in whole blood under flow conditions.  Surfaces were prepared 
and blood was drawn through the perfusion chamber for 5 min as described in Methods.  
Results shown for surface coverage (i) mean height (ii) and ZV50 (iii) are mean values of 
thirteen separate donors ± S.E. 
 
Figure 4. Inhibition of platelet adhesion, rolling and thrombus formation on intact and 
cleaved VWF using anti-αIIbβ3 and anti-GpIbα compounds. (A) Binding of washed 
platelets to intact and cleaved VWF in xCELLigence solid phase binding assays. Collagen type 
I, autolysed MMP-13 and BSA were used as control substrates. * p < .05, ** p < .01; (one-way 
ANOVA and post-hoc Tukey HSD test). Where indicated, washed platelets were pre-incubated 
with 1 or 10 µM anti-αIIbβ3 and/or 10 or 50 µg/ml anti-GpIbα compounds. (B) Whole blood 
platelet rolling at a shear rate of 1000s-1 on intact (green symbols) and cleaved (red symbols) 
VWF respectively. Where indicated, washed platelets were pre-incubated with 10 µM anti-
αIIbβ3 and/or 50 µg/ml anti-GpIbα compounds. (C) Results are shown for (i) surface coverage 
(ii) mean height and (iii) ZV50. Results are mean values of four separate donors ± S.E. 
 
Figure 5. GpIbα and P-selectin expression on platelets following whole blood flow 
experiments. Whole blood was drawn through a flow chamber for 5 min over intact or cleaved 
VWF using a syringe pump to generate a wall shear rate of 1000s-1, corresponding to arteriolar 
conditions.  Adherent platelets were then fixed in formalin prior to GpIbα and P-selectin 
detection using FITC Alexa-647 conjugated secondary antibodies respectively. (A) 
 23 
Representative images of protein expression. (B) Overall fluorescence and fold change of 
GpIbα and P-selectin expression were calculated using Mean Gray value in ImageJ1.35. (C) 
Fluorescent surface area of GpIbα and P-selectin expression were determined following 
thresholding of images in ImageJ1.35. Data are the mean ± S.E. of nine separate donors.  ** p 
< .005; (two-tailed paired t-Test). 
 
Figure 6. Platelet adhesion and thrombus deposition on VWF co-coated with fibrillar type 
I collagen. (A) Surface coverage (i) mean height (ii) and ZV50 (iii) of thrombi formed on 10 
µg/ml intact and cleaved VWF co-coated with 100 µg/ml type I collagen fibres. Surface 
coverage (i) mean height (ii) and (iii) ZV50 are the mean ± S.E. of nine different donors;* p < 
.05 (one-way ANOVA and Tukey post-hoc HSD test). Representative images of thrombi 
formed on intact and cleaved VWF co-coated with type I collagen fibres as described above. 
(C) Mean particle count and size were obtained from ImageJ1.35-thresholded images. * p < 
.05; ** p < .01; *** p < .001; (two-tailed paired t-Test). Data are th mean ± S.E. of nine 
different donors. 
 
Figure 7. Representative image of thrombus contraction on intact and cleaved VWF co-
coated with fibrillar type I collagen. Whole blood at a shear rate of 1000s-1 was drawn over 
intact and cleaved VWF co-coated with fibrillar type I collagen for 5 min with an image of 
field size 360 μm × 360 μm taken once every 5 s. Following acquisition, images were 
thresholded in ImageJ1.35 and the final image, at t = 300 s, was subtracted from that obtained 
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